CMS Open Payments · Program Year 2024
Spineology Inc.
Spineology Inc. reported $923,767.91 across General Payments, Research, and Ownership to 1,284 physicians and teaching hospitals across 1,323 transactions.
- $923.8K
- All-tracks total
- 1,323
- Transactions
- 1,284
- Recipients
- −$55.1K
- General Payments vs PY2023
Spineology Inc. reported $923,767.91 across all CMS Open Payments tracks (General + Research + Ownership) to 1,284 physicians and teaching hospitals in Program Year 2024 - ranking #638 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $535,215.10, averaging $719.45 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer spineology-inc Spineology Inc.
$923.8K · #638/1,925 · 0.0% industry · PY2024
- TOT $923.8K
- RANK #638
- SHARE 0.0%
- TXN 1,323
- RCP 1,284
- CAT 7
- GEN $535.2K
- ΔGEN −$55.1K
- TOP1 8.0%
- PY 2024
Volume peers
Nearest volume peer: Aesculap, Inc. ($921.5K)
Spineology Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Spineology Inc.'s CMS-reported General Payments decreased by $55.1K (−9.3%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: SPINEOLOGY INC.PY2023: SPINEOLOGY INC.PY2024: Spineology Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $590,301.87
- PY2024
- $535,215.10
What the Data Shows for Spineology Inc.
$923,767.91: that is what Spineology Inc. reported in payments to 1,284 physicians and teaching hospitals during Program Year 2024, spread across 1,323 transactions ($698.24 per transaction, $719.45 per recipient). The company sits at rank #638 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 7 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $138.4K across 96 transactions, 25.9% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Spineology Inc.'s 7-category general-payment breakdown at $138.4K, 25.9% of the reported total.
Spineology Inc. reports 7 general-payment categories - the top three are Compensation for Services Other Than Consulting (25.9%), Travel and Lodging (22.4%), and Royalty or License (17.7%). The remaining 4 categories make up 34.1% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Spineology Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $138.4K | 96 | 25.9% |
| Travel and Lodging | $119.8K | 202 | 22.4% |
| Royalty or License | $94.5K | 141 | 17.7% |
| Food and Beverage | $73.5K | 732 | 13.7% |
| Consulting Fee | $59.3K | 39 | 11.1% |
| Space Rental or Facility Fees | $46.1K | 9 | 8.6% |
| Entertainment | $3.6K | 65 | 0.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $177,966.36 (33.3%) of $535,215.10 in this company's General Payments records across 323 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Spineology Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Michael Wang
$42,579.12 across 55 reported transactions
- 2
Betsy Grunch
$41,318.19 across 76 reported transactions
- 3
Clifford Tribus
$40,139.02 across 12 reported transactions
- 4
Samuel Joseph Jr
$27,556.90 across 33 reported transactions
- 5
Michael Song
$26,373.13 across 33 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Spineology Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Spineology Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Spineology Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Zealand Pharma A/S
ImmunoGen, Inc.
Cumberland Pharmaceuticals, Inc.
Rapid Medical Ltd
Millennium Spine, LLC
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.